.png){kind=small}
At the PharmAsia Summit – Shanghai, Elsevier and BayHelix will focus on new R&D and commercial models in a rapidly changing China. Given demographic changes and China's massive health care reforms, opportunities abound - but so do potential pitfalls. Tapping the unmet medical need present in China provides Pharma with one of its few growth bright spots. But achieving this growth will require new models and flexibility: smaller cities are now growing faster than Tier I cities presenting logistical challenges; off-patent medications are under severe pricing pressure, which could limit the widespread uptake of branded generics. While support for biopharma innovation is a major government goal, so is curbing healthcare inflation. How can Pharmas collaborate and thrive in this environment?
At the PharmAsia Summit, top industry leaders from China and the West will discuss new growth models for China via a series of case studies, panels and keynotes.
To kick-off the Summit, we will release our 2nd annual PharmAsia Summit Report, in collaboration with McKinsey & Co., providing an in-depth analysis of trends critical to biopharmaceutical development and commercialization in the China market. The agenda for the PharmAsia Summit is developed by an organizing committee chaired by Steve Yang, PhD, VP, Head of Asia and Emerging Markets iMed, AstraZeneca PLC.
Top 10 Reasons to Attend PharmAsia Summit:
Hear about BD Success in China: The hottest China-based deal makers are sharing their first-hand experience in what deal structures work best to promote a given strategy.
The Best Networking in the Business: BayHelix and the PharmAsia News Editorial team bring you an unprecedented level of expertise and top analysis to our conference content.
Expand your Business and Your Career: Network at 9+ opportunities including the Welcome Reception and Gala Reception.
Case Studies: PharmAsia Summit is strategically packed with lessons learned and actionable data to help improve your business model in Asia.
Strategic Report: All attendees receive an exclusive report on how to enable innovation and drive growth in China in an environment of intensifying costs, based on an industry survey and discussions with key opinion leaders.
Get a Global Picture: Multinational companies and attendees from various countries will attend to do business with established and emerging companies.
Hear First-Hand Regulatory Insight: Accelerate time to market by learning about joint venture and Asia-based clinical trial designs, which multi-nationals can use to accelerate the development time line to launch products more rapidly in China.
Benchmark your China Business Model against the Best and the Brightest: Get a clear picture of what it takes to win in China and Asia by benchmarking your strategies to the best in class.
Bridge China’s Affordability Gap: Learn from specific case studies on how companies are improving market access to high-priced therapeutics and experimenting with different pricing strategies.
Define A China-based Innovation Strategy: Find out what how some heads of China are prioritizing their R & D opportunities in China that make the most sense.
